Two Immunoassays Compared for Determination of Serum Vitamin D
By LabMedica International staff writers Posted on 06 Jul 2021 |
Image: The IDS-iSYS Multi-Discipline Automated System Analyzer (Photo courtesy of Immunodiagnostic Systems)
Vitamin D is a fat-soluble steroid prohormone that is generated mainly in the skin by photochemical conversion of 7-dehydrocholesterol. 25-hydroxyvitamin D (25(OH)D) is its main storage form and is present in blood at very high concentration with respect to the active form 1,25-dihydroxyvitamin D.
The difficulties in the determination of 25(OH)D are related to its fat soluble nature, as well as its strong binding to the vitamin D binding protein (VDBP) and to serum albumin. On the other hand, although it would be appropriate for the different immunoassays to detect vitamin D2 and D3 in equimolar form, this is not usually fulfilled.
Clinical Biochemists at the Hospital Universitario Miguel Servet (Zaragoza, Spain) carried out a transversal descriptive observational study on a total of 184 individuals. The median age of the total of patients was 61 years old, with a minimum of 1 year and a maximum of 92. There were 31.5% men and 68.5% women. The samples came from both healthy patients and patients with various pathologies as bone, kidney, thyroid, cardiovascular, immune, neurological diseases and cancer.
The concentration of 25(OH)D was measured, as routine health analysis, by the automated IDS-iSYS 25VitD assay in an IDS-iSYS Multi-Discipline Automated System Analyzer (Vitro, Immunodiagnostic Systems Holdings PLC, Boldon Colliery, UK), which uses a chemiluminescence technology, which is fully automated. The same samples were processed by the Alinity i 25-OH Vitamin D assay in an Alinity i automated Analyzer (Abbott, Abbott Park, IL, USA), which is a one-step delayed-action immunoassay using chemiluminescent microparticles immunoassay (CMIA) technology.
The scientists reported that of the total patients, 52.7% received vitamin D supplements. The correlation coefficient of agreement for general group, supplementation group and group without supplementation was 0.92, 0.91 and 0.89, respectively. In all of them, a kappa index>0.75 was obtained. The mean value of the bias was higher for the supplemented group (−20.4 nmol/L) than for the group without treatment (−4.9 nmol/L). Graphically, a greater concordance between both assays was observed when patients receiving vitamin D supplements were excluded. The team observed lower concentrations of 25(OH)D in the IDS-iSYS 25 VitD assay when compared to the results obtained with the Alinity i 25-OH Vitamin D assay.
The authors concluded that the assays evaluated were not comparable to each other. Despite this, they show an excellent concordance in the evaluation of the vitamin D status. The study was published on June 23, 2021 in the journal Practical Laboratory Medicine.
Related Links:
Hospital Universitario Miguel Servet
Immunodiagnostic Systems Holdings PLC
Abbott
The difficulties in the determination of 25(OH)D are related to its fat soluble nature, as well as its strong binding to the vitamin D binding protein (VDBP) and to serum albumin. On the other hand, although it would be appropriate for the different immunoassays to detect vitamin D2 and D3 in equimolar form, this is not usually fulfilled.
Clinical Biochemists at the Hospital Universitario Miguel Servet (Zaragoza, Spain) carried out a transversal descriptive observational study on a total of 184 individuals. The median age of the total of patients was 61 years old, with a minimum of 1 year and a maximum of 92. There were 31.5% men and 68.5% women. The samples came from both healthy patients and patients with various pathologies as bone, kidney, thyroid, cardiovascular, immune, neurological diseases and cancer.
The concentration of 25(OH)D was measured, as routine health analysis, by the automated IDS-iSYS 25VitD assay in an IDS-iSYS Multi-Discipline Automated System Analyzer (Vitro, Immunodiagnostic Systems Holdings PLC, Boldon Colliery, UK), which uses a chemiluminescence technology, which is fully automated. The same samples were processed by the Alinity i 25-OH Vitamin D assay in an Alinity i automated Analyzer (Abbott, Abbott Park, IL, USA), which is a one-step delayed-action immunoassay using chemiluminescent microparticles immunoassay (CMIA) technology.
The scientists reported that of the total patients, 52.7% received vitamin D supplements. The correlation coefficient of agreement for general group, supplementation group and group without supplementation was 0.92, 0.91 and 0.89, respectively. In all of them, a kappa index>0.75 was obtained. The mean value of the bias was higher for the supplemented group (−20.4 nmol/L) than for the group without treatment (−4.9 nmol/L). Graphically, a greater concordance between both assays was observed when patients receiving vitamin D supplements were excluded. The team observed lower concentrations of 25(OH)D in the IDS-iSYS 25 VitD assay when compared to the results obtained with the Alinity i 25-OH Vitamin D assay.
The authors concluded that the assays evaluated were not comparable to each other. Despite this, they show an excellent concordance in the evaluation of the vitamin D status. The study was published on June 23, 2021 in the journal Practical Laboratory Medicine.
Related Links:
Hospital Universitario Miguel Servet
Immunodiagnostic Systems Holdings PLC
Abbott
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms